

This article was downloaded by:

On: 23 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713617200>

### Synthesis of $\beta$ -Glucuronides of Estradiol, Ethynylestradiol and Estrone

Barbara Werschkun; Karin Gorziza; Joachim Thiem

**To cite this Article** Werschkun, Barbara , Gorziza, Karin and Thiem, Joachim(1999) 'Synthesis of  $\beta$ -Glucuronides of Estradiol, Ethynylestradiol and Estrone', *Journal of Carbohydrate Chemistry*, 18: 6, 629 – 637

**To link to this Article:** DOI: 10.1080/07328309908544025

URL: <http://dx.doi.org/10.1080/07328309908544025>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## SYNTHESIS OF $\beta$ -GLUCURONIDES OF ESTRADIOL, ETHYNYLESTRADIOL AND ESTRONE

Barbara Werschkun, Karin Gorziza and Joachim Thiem\*

Institut für Organische Chemie, Universität Hamburg, Martin-Luther-King-Platz 6,  
D-20146 Germany


*Received November 10, 1998 - Final Form April 7, 1999*

### ABSTRACT

Improved syntheses for the 3- $\beta$ -D-glucuronides of the steroidal sex hormones 17 $\beta$ -estradiol, 17 $\alpha$ -ethynylestradiol and estrone are reported employing boron trifluoride diethyl etherate catalysis with tetraacetylated glucuronic acid or the corresponding imidate.

### INTRODUCTION

In 1971 Conrow and Bernstein published an improved Koenigs-Knorr synthesis of aryl glucuronides using cadmium carbonate as the acid acceptor to give the the 3- $\beta$ -D-glucuronide of the naturally occurring estrogen, estrone.<sup>1</sup> Previously standard Koenigs-Knorr reactions using silver carbonate gave maximum yields of 10%,<sup>2,3</sup> and by employing unprotected 17 $\beta$ -estradiol only bisglucosiduronate (2%) was found.<sup>2</sup> Hadd *et al.* tried the CdCO<sub>3</sub> method with the synthetic component of many oral contraceptive agents, 17 $\alpha$ -ethynylestradiol. Contrary to their expectation, they obtained more 17 $\beta$ -glucuronide (5%) than 3-linked glycoside and as the main product (7%) the 3,17-bisglucuronide.<sup>4</sup> Conrow and Bernstein avoided that problem by using the formate-protected 17 $\beta$ -estradiol to achieve 71% of the 3-glucuronidated steroid.<sup>1</sup>



	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>
3	OH	OH	H
4	OH	OAc	H
5	OH	=O	
6	OH	OH	C≡CH
7	OAc	OAc	C≡CH
8	OH	OAc	C≡CH

Scheme 1


With regard to the particular biological and medical importance of steroidal estrogens and investigation into their glucuronic acid conjugates as significant metabolites a more convenient method for preparing glucuronides of estradiol and ethynylestradiol was required. Recently an alternative access was presented by the enzymatic synthesis of these conjugates on a preparative scale employing UDP-glucuronyl transferase.<sup>5</sup>

To improve the classical synthesis of aryl glycosides by Helferich *et al.*<sup>6</sup> we combined the findings of Bretschneider *et al.*,<sup>7</sup> who converted phenols and glucose pentaacetate into the corresponding aryl  $\beta$ -D-glucopyranosides using boron trifluoride in anisole as catalyst, with the imidate method utilizing  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ .<sup>8</sup> Similarly, the same procedure could be achieved to give morphine and coumarin glucuronide derivatives in good yields.<sup>9,10</sup>

## RESULTS AND DISCUSSION

Starting from D-glucuronolactone the peracetylated glucuronic methyl ester 1 could be prepared as the crystalline  $\beta$ -anomer in one step.<sup>11</sup> Conversion of the acetate by a standard method gave the glycosyl bromide and successive treatment with silver(I) oxide and trichloroacetonitrile led to the well-known  $\alpha$ -imidate 2.<sup>8,12</sup>

The 17 $\beta$ -hydroxyl group of estradiol 3 was selectively protected by transesterification with an excess of methyl acetate in cyclohexane to give 17-acetate 4.<sup>13</sup> For selective protection of the propargyl compound 6 two steps were necessary: First both OH-groups were acetylated to give 7, then with potassium carbonate in methanol the phenolic acetyl group was removed resulting in 8 with 66% yield (see Scheme 1).



Scheme 2

For glucuronation, facile reaction conditions employing equimolar amounts of boron trifluoride etherate in anhydrous dichloromethane were tested. By this method the 3- $\beta$ -D-glucuronide triacetate methyl ester of estradiol and estrone (9 and 11) could be obtained after crystallisation in 42% yield. Convincing yields for such glucuronic acid conjugates were achieved, and the inconvenient use of glycosyl halides and catalysis with heavy metal salts was avoided. With ethynylestradiol 8 as aglycon the same procedure yielded only 11% of the expected product 13. Better results (61%) were obtained with the activated glucuronic acid imidate 2 and catalytic amounts of  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  (see Scheme 2).

For ester hydrolysis and deacetylation of the products, treatment with sodium hydroxide in methanol gave the corresponding glucuronides **10**, **12** and **14**. The progress of the reaction for ethynyl conjugate **13** could not be monitored by TLC; cleavage of the sugar acetate groups was faster than of the steroid 17-acetyl group, and monoacetylated and fully deblocked compounds had the same  $R_f$  values. Therefore, the reaction was stopped after two days, worked up and completion monitored by  $^1\text{H}$  NMR.

## EXPERIMENTAL

**General methods.** Melting points were determined using an Olympus polarizing microscope with a Mettler FP 82 heating desk and are uncorrected. Optical rotations were measured with Perkin-Elmer polarimeter 243 or 341. NMR spectra were recorded on Bruker AMX-400 NMR spectrometer (400 MHz for  $^1\text{H}$  and 100.67 MHz for  $^{13}\text{C}$ ). HRMS spectra were determined with a VG Analytical 70-250S mass spectrometer, using the FAB ion source, 3-nitrobenzyl alcohol as matrix and polyethylene glycol (average mass of 300 or 600, respectively) as reference. MALDI-TOF spectra were recorded on Bruker Biflex III. TLC were run on precoated plates, silica gel 60 GF<sub>254</sub> (Merck). Detection was effected by observation under UV light at 254 nm, and by spraying with 10% ethanolic sulfuric acid and subsequent heating. Column chromatography was performed by flash technique using silicagel 60 (0.040-0.063 mm, Merck).

**3,17 $\beta$ -Diacetoxy-17 $\alpha$ -ethynyl-1,3,5[10]-estratriene (7).**<sup>14</sup> A solution of ethynyl-estradiol **6** (3.0 g, 10 mmol) in pyridine (30 mL) and acetic anhydride (30 mL) was stirred at 100 °C for 2 d. The solvent was evaporated under reduced pressure to give **7** as a colourless foam (3.81 g, quantitative):  $[\alpha]_D^{20} -1.1^\circ$  ( $c$  0.5, chloroform);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.83 (s, 3H, Me), 1.31-1.46 (m, 4H), 1.63-1.70 (m, 1H), 1.75-1.83 (m, 3H), 1.93-2.03 (m, 2H), 1.99 (s, 3H, OAc), 2.16-2.23 (m, 1H), 2.21 (s, 3H, OAc), 2.29-2.33 (m, 1H), 2.56 (s, 1H,  $\equiv\text{CH}$ ), 2.68-2.80 (m, 3H), 6.72 (d, 1H, Ar), 6.78 (dd, 1H, Ar), 7.22 (d, 1H, Ar);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  12.95 (Me), 20.70, 21.02 (2 acetyl-Me), 22.86, 25.73, 26.65, 29.09, 32.67, 36.92 (6  $\text{CH}_2$ ), 38.33, 43.18, 47.39, 47.42 (4 CH), 74.50, 82.92, 84.01 (3 quart. C), 118.18, 121.07, 126.01 (3 Ar-CH), 137.34, 137.73 (2 quart. Ar-C), 148.01 (Ar-C-O), 169.17, 169.41 (2  $\text{CO}_2$ ).

**17 $\beta$ -Acetoxy-17 $\alpha$ -ethynyl-3-hydroxy-1,3,5[10]-estratriene (8).** A solution of peracetylated ethynylestradiol **7** (4.01 g, 10.6 mmol) and potassium carbonate (700 mg, 5 mmol) in anhydrous methanol (50 mL) was stirred at room temperature for 0.5 h. After filtration and concentration under reduced pressure, the residual crude product was purified by column chromatography with dichloromethane to give **8** as a colourless foam (2.36 g, 66%):  $[\alpha]_{\text{D}}^{20}$   $-0.4^\circ$  (*c* 0.5, chloroform);  $^1\text{H NMR}$  ( $\text{CDCl}_3$ )  $\delta$  0.84 (s, 3H, Me), 1.26-1.46 (m, 4H), 1.62-1.70 (m, 1H), 1.74-1.82 (m, 3H), 1.92-2.03 (m, 2H), 1.99 (s, 3H, OAc), 2.11-2.22 (m, 1H), 2.26-2.31 (m, 1H), 2.56 (s, 1H,  $\equiv\text{CH}$ ), 2.68-2.78 (m, 3H), 4.66 (bs, 1H, OH), 6.50 (d, 1H, Ar), 6.57 (dd, 1H, Ar), 7.09 (d, 1H, Ar);  $^{13}\text{C NMR}$  ( $\text{CDCl}_3$ )  $\delta$  12.99 (Me), 21.04 (acetyl-Me), 22.87, 25.92, 26.81, 29.18, 32.69, 36.94 (6  $\text{CH}_2$ ), 38.69, 42.97, 47.38, 47.46 (4 CH), 74.50, 82.92, 84.12 (3 quart. C), 112.28, 114.80, 126.14 (3 Ar-CH), 132.03, 137.75 (2 quart. Ar-C), 152.94 (Ar-C-O), 169.32 ( $\text{CO}_2$ ).

**Methyl {(17 $\beta$ -Acetoxy-3-hydroxy-1,3,5[10]-estratrien-3-yl)-2,3,4-tri-*O*-acetyl- $\beta$ -D-glucopyranosid}uronate (9).** A solution of estradiol 17-acetate **4** (2.30 g, 7.3 mmol) and peracetylated glucuronic methyl ester **1** (2.75 g, 7.3 mmol) in anhydrous dichloromethane (50 mL) was treated with boron trifluoride diethyl etherate (1.85 mL, 15 mmol) and stirred at room temperature overnight. The mixture was washed twice with saturated sodium hydrogen carbonate solution, dried over magnesium sulfate and concentrated under reduced pressure. Recrystallization (twice) from acetone gave **9** as colourless crystals (1.82 g, 42%): mp 225-227  $^\circ\text{C}$ ;  $[\alpha]_{\text{D}}^{20}$   $+3.9^\circ$  (*c* 0.5, chloroform);  $^1\text{H NMR}$  ( $\text{CDCl}_3$ )  $\delta$  0.75 (s, 3H, Me), 1.17-1.51 (m, 7H), 1.64-1.70 (m, 1H), 1.81 (d, 2H), 1.97, 1.98, 1.98, 1.99 (4s, 12H, 4 OAc), 2.13-2.22 (m, 3H), 2.75-2.77 (m, 2H), 3.67 (s, 3H, OMe), 4.09 (d, 1H, H-5,  $J_{4,5} = 9.5$  Hz), 4.61 (dd  $\sim$  t, 1H, H-17'), 5.03 (d, 1H, H-1,  $J_{1,2} = 7.6$  Hz), 5.18-5.27 (m, 3H, H-2, H-3, H-4), 6.64 (d, 1H, Ar), 6.70 (dd, 1H, Ar), 7.13 (d, 1H, Ar);  $^{13}\text{C NMR}$  ( $\text{CDCl}_3$ )  $\delta$  11.61 (Me), 20.09, 20.20, 20.76 (4 acetyl-Me), 22.80, 25.69, 26.64, 27.11, 29.25, 36.41 (6  $\text{CH}_2$ ), 37.95 (CH), 42.44 (quart. C), 43.42, 49.33 (2 CH), 52.53 (OMe), 68.80, 70.02, 71.51, 72.24, 82.22 (5 CH-O), 98.87 (O-CH-O), 113.88, 116.67, 126.09 (3 Ar-CH), 135.08, 137.85 (2 quart. Ar-C), 154.19 (Ar-C-O), 166.47, 168.80, 168.92, 169.72, 170.80 (5  $\text{CO}_2$ ); MALDI-TOF-MS:  $m/z$  653.10  $[\text{M}+\text{Na}]^+$ , 669.08  $[\text{M}+\text{K}]^+$ .

Anal. Calcd for  $C_{33}H_{42}O_{12}$  (630.69): C, 62.85; H, 6.71. Found: C, 62.83; H, 6.78.

**(3,17 $\beta$ -Dihydroxy-1,3,5[10]-estratrien-3-yl)  $\beta$ -D-Glucopyranosiduronic Acid (10).** Glucuronide **9** (1.72 g, 2.7 mmol) was suspended in methanol (200 mL) and 2N sodium hydroxide solution (15 mL). The clear solution was stirred at room temperature overnight, the reaction being monitored by TLC (butan-1-ol/water/acetone/glacial acetic acid/25% aq. ammonia 70:60:50:18:1.5). After acidifying with ion-exchange resin Amberlite IR 120 H<sup>+</sup>, filtration and concentration under reduced pressure, the residue obtained was recrystallized from methanol/water to give **10** as colourless crystals (1.03 g, 84%): mp 193-195 °C;  $[\alpha]_D^{20}$  -9.0° (*c* 1, methanol); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta$  0.69 (s, 3H, Me), 1.12-1.38 (m, 7H), 1.60 (m, 1H), 1.85-1.92 (m, 3H), 2.12 (m, 1H), 2.28 (m, 1H), 2.77 (m, 2H), 3.25-3.35 (m, 2H), 3.42 (dd ~ t, 1H), 3.54 (dd ~ t, 1H), 3.86 (d, 1H, H-5,  $J_{4,5} = 9.7$  Hz), 4.95 (d, 1H, H-1,  $J_{1,2} = 7.6$  Hz), 6.71 (d, 1H, Ar), 6.78 (dd, 1H, Ar), 7.19 (d, 1H, Ar); <sup>13</sup>C NMR (methanol-*d*<sub>4</sub>)  $\delta$  9.14 (Me), 21.47, 24.95, 25.84, 28.14, 28.18, 35.44 (6 CH<sub>2</sub>), 37.75 (CH), 41.78 (quart. C), 42.85, 48.75 (2 CH), 70.45, 72.07, 74.79, 79.91 (5 CH-O), 100.27 (O-CH-O), 112.81, 115.50, 124.72 (3 Ar-CH), 133.42, 136.50 (2 quart. Ar-C), 154.17 (Ar-C-O), 169.63 (CO<sub>2</sub>); HRMS: *m/z* 449.2149 [M+H]<sup>+</sup> (C<sub>24</sub>H<sub>33</sub>O<sub>8</sub> requires 449.2175).

**Methyl {(17-Oxo-1,3,5[10]-estratrien-3-yl)-2,3,4-tri-*O*-acetyl- $\beta$ -D-glucopyranosid}uronate (11).** Glucuronidation [estrone **5** (2.0 g, 5.31 mmol), compound **1** (2.78 g, 7.39 mmol), CH<sub>2</sub>Cl<sub>2</sub> (40 mL), BF<sub>3</sub>·Et<sub>2</sub>O (2 mL, 14.8 mmol)], as described for **9**, afforded **11** as colourless crystals (1.34 g, 42%): mp 213-215 °C;  $[\alpha]_D^{20}$  +56.4° (*c* 1, chloroform), {lit.<sup>2</sup>  $[\alpha]_D^{23} +53.6 \pm 0.4$ }; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (s, 3H, Me), 1.37-1.64 (m, 7H), 1.92-1.99 (m, 2H), 2.02, 2.04, 2.05 (3s, 9H, 3 OAc), 2.06-2.13 (m, 1H), 2.14-2.18 (m, 1H), 2.20-2.27 (m, 1H), 2.35-2.40 (m, 1H), 2.45-2.53 (m, 1H), 2.85-2.89 (m, 1H), 3.72 (s, 3H, OMe), 4.13-4.17 (m, 1H, H-5), 5.09 (d, 1H, H-1,  $J_{1,2} = 7.1$  Hz), 5.22-5.33 (m, 3H, H-2, H-3, H-4), 6.72 (d, 1H, Ar-H), 6.78 (dd, 1H, Ar-H), 7.19 (d, 1H, Ar-H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  14.25 (Me), 20.92, 21.00, 21.03 (3 acetyl-Me), 21.99, 26.27, 26.82, 29.99, 31.98, 36.26 (6 CH<sub>2</sub>), 38.62, 44.47 (2 CH), 48.37 (quart. C), 50.84 (CH), 53.36 (OMe), 69.67, 71.52, 72.38, 73.14 (C-2, C-3, C-4, C-5), 99.71 (C-1), 114.85, 117.63, 126.93 (3 Ar-CH), 135.46, 138.55 (2 quart. Ar-C), 155.17 (Ar-C-O), 167.32, 169.62, 169.74, 170.54 (4 CO<sub>2</sub>); MALDI-TOF-MS: *m/z* 609.07 [M+Na]<sup>+</sup>.

Anal. Calcd for  $C_{31}H_{38}O_{11}$  (586.64): C, 63.47; H, 6.53. Found: C, 63.30; H, 6.60.

**(17-Oxo-1,3,5[10]-estratrien-3-yl)  $\beta$ -D-Glucopyranosiduronic Acid (12).**

Compound **11** (204 mg, 0.339 mmol) was deacetylated by the same procedure [MeOH (40 mL), 2N NaOH solution (2 mL), stirred overnight] as for compound **10**. The obtained residue was recrystallized from methanol/water to give **12** as colourless crystals (142 mg, 94%): mp 144–147 °C, {lit,<sup>1</sup> mp 150–170 °C}; [ $\alpha$ ]<sup>20</sup><sub>D</sub> +35.5° (*c* 1, methanol), {lit,<sup>1</sup> [ $\alpha$ ]<sup>20</sup><sub>D</sub> +63° (*c* 0.72, methanol)}; <sup>1</sup>H NMR (methanol-*d*<sub>4</sub>)  $\delta$  0.85 (s, 3H, Me), 1.31–1.65 (m, 6H), 1.80–1.85 (m, 1H), 1.92–2.13 (m, 3H), 2.15–2.22 (m, 1H), 2.32–2.28 (m, 1H), 2.39–2.47 (m, 1H), 2.78–2.84 (m, 2H), 3.38–3.44 (m, 2H), 3.52–3.58 (m, 1H), 3.87 (d, 1H, H-5,  $J_{4,5} = 9.7$  Hz), 4.84 (d, 1H, H-1,  $J_{1,2} = 7.6$  Hz), 6.74 (d, 1H, Ar-H), 6.79 (dd, 1H, Ar-H), 7.14 (d, 1H, Ar-H); <sup>13</sup>C NMR (methanol-*d*<sub>4</sub>)  $\delta$  14.70 (Me), 22.91, 27.45, 28.05, 31.01, 33.23, 37.14 (6 CH<sub>2</sub>), 40.16, 45.80 (2 CH), 48.37 (quart. C), 52.08 (CH), 73.46, 75.06, 77.02, 77.81 (C-2, C-3, C-4, C-5), 103.22 (C-1), 115.90, 118.53, 127.69 (3 Ar-CH), 135.83, 139.40 (2 quart. Ar-C), 157.31 (Ar-C-O); HRMS: *m/z* 447.1990 [M+H]<sup>+</sup> (C<sub>24</sub>H<sub>31</sub>O<sub>8</sub> requires 447.2019).

**Methyl ((17 $\beta$ -Acetoxy-17 $\alpha$ -ethynyl-3-hydroxy-1,3,5[10]-estratrien-3-yl)-2,3,4-tri-*O*-acetyl- $\beta$ -D-glucopyranosid)uronate (13).** A solution of glycosyl imidate **2** (2.8 g, 5.9 mmol) and ethynylestradiol 17-acetate **8** (2.1 g, 6.2 mmol) in anhydrous dichloromethane (150 mL) was treated with three drops of boron trifluoride diethyl etherate at -20 °C and stirred for 0.5 h. The mixture was washed with saturated sodium hydrogen carbonate solution, dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by column chromatography with petroleum ether/ethyl acetate (3:1) to give **13** as a colourless foam (2.3 g, 61%): [ $\alpha$ ]<sup>20</sup><sub>D</sub> -27.2° (*c* 1, chloroform); <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.89 (s, 3H, Me), 1.34–1.51 (m, 4H), 1.68–1.89 (m, 4H), 1.98–2.06 (m, 2H), 2.03, 2.04, 2.06, 2.08 (4s, 12H, 4 OAc), 2.08–2.10 (m, 1H), 2.20–2.37 (m, 1H), 2.62 (s, 1H,  $\equiv$ CH), 2.73–2.84 (m, 3H), 3.73 (s, 3H, OMe), 4.16 (d, 1H, H-5,  $J_{4,5} = 9.7$  Hz), 5.10 (d, 1H, H-1,  $J_{1,2} = 7.6$  Hz), 5.23–5.35 (m, 3H, H-2, H-3, H-4), 6.70 (d, 1H, Ar), 6.77 (dd, 1H, Ar), 7.20 (d, 1H, Ar); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  12.96 (Me), 20.06, 20.18, 21.00 (3 acetyl-Me), 22.84, 25.84, 26.72, 29.27, 32.66, 36.91 (6 CH<sub>2</sub>), 38.53, 43.05, 47.39 (3 CH), 52.50 (OMe), 68.80, 70.63, 71.52, 72.21 (C-2, C-3,



C-4, C-5), 74.51, 82.92, 83.99 (3 quart. C), 98.81 (C-1), 113.89, 116.65, 126.10 (3 Ar-CH), 134.94, 137.80 (2 quart. Ar-C), 154.20 (Ar-C-O), 166.46, 168.75, 168.89, 169.11, 169.66 (5 CO<sub>2</sub>); HRMS:  $m/z$  653.2621 [M+H]<sup>+</sup> (C<sub>35</sub>H<sub>41</sub>O<sub>12</sub> requires 653.2598).

**(3,17 $\beta$ -Dihydroxy-17 $\alpha$ -ethynyl-1,3,5[10]-estratrien-3-yl)  $\beta$ -D-Glucopyranosiduronic Acid (14).** Compound 13 (659 mg, 1 mmol) was deacetylated by the same procedure (75 mL MeOH, 5 mL 2N NaOH solution, stirred for 2 d) as for compound 10. The raw material was purified by column chromatography with chloroform/methanol/acetic acid (25:5:1) to yield 14 as a yellowish solid (349 mg, 74%):  $[\alpha]_D^{20}$  -13.5° (*c* 0.5, methanol); <sup>1</sup>H NMR (methanol d<sub>4</sub>)  $\delta$  0.72 (s, 3H, Me), 1.16-1.37 (m, 4H), 1.57-1.65 (m, 3H), 1.71-1.89 (m, 3H), 1.99-2.06 (m, 1 H), 2.08-2.14 (m, 1 H), 2.18-2.26 (m, 1H), 2.65-2.70 (m, 2H), 2.74 (s, 1H,  $\equiv$ CH), 3.31-3.34, 3.42-3.49 (2m, 2H, 1H, H-2, H-3, H-4), 3.78 (d, 1H, H-5,  $J_{4,5}$  = 9.7 Hz), 4.75 (d, 1H, H-1,  $J_{1,2}$  = 7.6 Hz), 6.63 (d, 1H, Ar), 6.70 (dd, 1H, Ar), 7.06 (d, 1H, Ar); <sup>13</sup>C NMR (methanol-d<sub>4</sub>)  $\delta$  13.71 (Me), 24.12, 28.03, 28.93, 31.16, 34.46, 40.31 (6 CH<sub>2</sub>), 41.33, 45.59, 51.18 (3 CH), 48.63 (quart. C), 73.45, 75.06, 77.81 (4 CH-O), 80.77 (quart. C-O), 103.26 (O-CH-O), 115.85, 118.48, 127.70 (3 Ar-CH), 136.28, 139.47 (2 quart. Ar-C), 157.20 (Ar-C-O), 165.27 (CO<sub>2</sub>); MALDI-TOF-MS:  $m/z$  495.18 [M+Na]<sup>+</sup>, 517.16 [M-H+2Na]<sup>+</sup> (C<sub>26</sub>H<sub>32</sub>O<sub>8</sub> requires 472.54).<sup>15</sup>

## ACKNOWLEDGEMENTS

Support of this work by the Fonds der Chemischen Industrie and the Schering AG, Berlin is gratefully acknowledged. Thanks go to Kirsten Geisler for laboratory assistance and Lars Kröger for mass spectral analysis.

## REFERENCES AND NOTES

1. R. B. Conrow and S. Bernstein, *J. Org. Chem.*, **36**, 863 (1971).
2. H. H. Wotiz, E. Smakula, N. N. Lichtin and J. H. Leftin, *J. Am. Chem. Soc.*, **81**, 1704 (1959).
3. J. S. Elce, J. G. D. Carpenter and A. E. Kellie, *J. Chem. Soc.*, 542 (1967).
4. H. H. Hadd, W. Slikker, Jr., and E. D. Helton, *J. Steroid Biochem.*, **13**, 1107 (1980).

5. B. Werschkun, A. Wendt and J. Thiem, *J. Chem. Soc., Perkin Trans. 1*, 3021 (1998).
6. B. Helferich and E. Schmitz-Hillebrecht, *Ber. Dtsch. Chem. Ges.*, **66**, 378 (1933).
7. H. Bretschneider and K. Beran, *Monatsh.*, **80**, 262 (1949).
8. R. R. Schmidt and G. Grundler, *Synthesis*, 885 (1981).
9. B. Berrang, G. A. Brine and F. I. Carroll, *Synthesis*, 1165 (1997).
10. R. T. Brown, F. Scheinmann and A. V. Stachulski, *J. Chem. Res. Synop.*, 370 (1997).
11. G. N. Bollenback, J. W. Long, D. G. Benjamin and L. A. Lindquist, *J. Am. Chem. Soc.*, **77**, 3310 (1955).
12. B. Fischer, A. Nudelman, M. Ruse, J. Herzig, H. E. Gottlieb and E. Keinan, *J. Org. Chem.*, **49**, 4988 (1984).
13. E. Hecker, *Chem. Ber.*, **92**, 1386 (1959).
14. J. S. Mills, H. J. Ringold and C. Djerassi, *J. Am. Chem. Soc.*, **80**, 6118 (1958).
15. The structure of **14** could be determined only by NMR and MALDI-TOF-MS data and by characterization of the protected precursor compound **13**.